Asian Phytoceuticals PCLBKK:APCO-R 62 Debt-to-Equity is 0.02 as of Mar. 2026, which is 50% below its 10-year median of 0.04. GuruFocus rates BKK:APCO-R with a GF Score™ of 62/100 and a GF Value™ of ฿7.61. The stock has 4 warning signs investors should review. Among 1,739 Consumer Packaged Goods companies, Asian Phytoceuticals PCL ranks better than 95.17% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Asian Phytoceuticals PCL's Debt-to-Equity or its related term are showing as below:
BKK:APCO-R'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.08
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Asian Phytoceuticals PCL was 0.08. The lowest was 0.00. And the median was 0.04.
BKK:APCO-R's Debt-to-Equity is ranked better than 95.17% of 1739
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs BKK:APCO-R: 0.02
Asian Phytoceuticals PCL (BKK:APCO-R) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Asian Phytoceuticals PCL Debt-to-Equity Related Terms
Asian Phytoceuticals PCL Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:APCO-R vs PG, CL, KVUE: Debt-to-Equity Comparison
For the Household & Personal Products subindustry, Asian Phytoceuticals PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asian Phytoceuticals PCL Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Asian Phytoceuticals PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Asian Phytoceuticals PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asian Phytoceuticals PCL (BKK:APCO-R) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asian Phytoceuticals PCL and its competitors. This is 50% below median its historical median of 0.04. According to the industry distribution chart, Asian Phytoceuticals PCL ranks #84 out of 1739 companies in the Consumer Packaged Goods industry, placing it in the top 4.8%.
Is Asian Phytoceuticals PCL's Debt-to-Equity too high?
Asian Phytoceuticals PCL's current Debt-to-Equity of 0.02 is 50% below median its 10-year median of 0.04. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. Asian Phytoceuticals PCL's value of 0.02 is 95.1% below this industry median. Based on the distribution chart, Asian Phytoceuticals PCL ranks #84 out of 1739 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Asian Phytoceuticals PCL has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Asian Phytoceuticals PCL's Debt-to-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Asian Phytoceuticals PCL ranks #84 out of 1739 companies for Debt-to-Equity. This places Asian Phytoceuticals PCL in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. Asian Phytoceuticals PCL's value of 0.02 is 95.1% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.41, Asian Phytoceuticals PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,739 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asian Phytoceuticals PCL's current Debt-to-Equity of 0.02 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asian Phytoceuticals PCL and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asian Phytoceuticals PCL's current Debt-to-Equity is 0.02, which is 50% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asian Phytoceuticals PCL stock overvalued right now?
Asian Phytoceuticals PCL (BKK:APCO-R) has a current Debt-to-Equity of 0.02. The stock's GF Value™ is ฿7.61, compared to a current price of ฿6.27 — trading 17.6% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 50% below median its 10-year median of 0.04 and 95.1% below the Consumer Packaged Goods industry median of 0.41. Asian Phytoceuticals PCL's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Asian Phytoceuticals PCL (BKK:APCO-R), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asian Phytoceuticals PCL (BKK:APCO-R) Overvalued in 2026?
Based on GuruFocus' analysis, Asian Phytoceuticals PCL stock appears to be undervalued.
The current stock price of ฿6.27 is trading 17.6% below its estimated GF Value™ of ฿7.61.
Key valuation signals for BKK:APCO-R:
Debt-to-Equity: 0.02 (50% below median its 10-year median of 0.04)
GF Value™: ฿7.61 vs. price of ฿6.27 (17.6% below fair value)
Industry Position: 95.1% below the Consumer Packaged Goods median (#84 of 1739)
No single metric tells the full story. See the BKK:APCO-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asian Phytoceuticals PCL engages in the manufacturing and marketing of herbal healthcare products. The company engages in the production and distribution of dietary supplements, cosmetics, and personal care products made from natural herbs. Its beauty products include skin nourishing and skin care products, hair loss treatment and hair growth products, slimming products, dietary supplements, and other nutritional products. Geographically, the company offers its services only in Thailand.
62GF Score
Get the complete analysis for BKK:APCO-R
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:APCO-R has been successfully added to your 
